Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a pipeline of 9 oncology programs at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.
Looking for a particular Antengene employee's phone or email?
Antengene Questions
The Antengene annual revenue was $80 million in 2026.
Donald Lung is the Chief Financial Officer and Board Director of Antengene.
48 people are employed at Antengene.
Antengene is based in Changning, Shanghai.
The NAICS codes for Antengene are [541, 3254, 325, 54, 32541, 32].
The SIC codes for Antengene are [283, 28].
Top Antengene Employees
-
Bing Hou
Chief Scientific Officer at Antengene
Shanghai, China1 -
John Chin
Chief Business Officer at Antengene
Califon, NJ, US14 -
Yang Cao
Corporate Vice President at Antengene
Shanghai, China1 -
Linjie Tian
Director of Drug Discovery at Antengene
Rockville, MD, US1 -
11
